Cerus Reports Strong 2025 Financials, Exceeding $233M Revenue, Narrows Net Loss, Reaffirms 2026 Growth Guidance

summarizeSummary

Cerus Corporation announced robust full-year and fourth-quarter 2025 financial results, featuring significant revenue growth, a narrowed net loss, and reaffirmed positive guidance for 2026 product revenue.

check_boxKey Events

• Strong 2025 Revenue Growth

  Reported full-year 2025 total revenue of $233.8 million, a 16% increase from 2024, with product revenue growing 14% to $206.1 million.

• Improved Profitability Metrics

  GAAP net loss narrowed to $15.6 million for 2025, and non-GAAP adjusted EBITDA was positive $9.5 million, marking the second consecutive year of positive adjusted EBITDA.

• Reaffirmed 2026 Guidance

  Reaffirmed full-year 2026 product revenue guidance of $224 million to $228 million, representing 9% to 11% year-over-year growth.

• Strategic Market Expansion

  Entered a group purchasing agreement with Blood Centers of America (BCA), significantly expanding access to its licensed product portfolio across approximately 50% of the U.S. blood supply.

auto_awesomeAnalysis

Cerus Corporation delivered strong financial performance in 2025, marked by a 16% increase in total revenue to $233.8 million and a 14% rise in product revenue to $206.1 million. The company successfully narrowed its GAAP net loss and achieved positive non-GAAP adjusted EBITDA for the second consecutive year, demonstrating improved operational efficiency and financial health. The reaffirmation of 9-11% product revenue growth for 2026, alongside strategic achievements like the BCA group purchasing agreement and the initiation of a Phase 4 clinical study, indicates continued positive momentum and strengthens the company's market position in safeguarding the global blood supply. Investors should note the consistent execution and positive outlook.